IRD vs. NGNE, TVRD, BTMD, SLRN, TVGN, CGC, PRQR, NBTX, YMAB, and IMAB
Should you be buying Opus Genetics stock or one of its competitors? The main competitors of Opus Genetics include Neurogene (NGNE), Tvardi Therapeutics (TVRD), biote (BTMD), Acelyrin (SLRN), Semper Paratus Acquisition (TVGN), Canopy Growth (CGC), ProQR Therapeutics (PRQR), Nanobiotix (NBTX), Y-mAbs Therapeutics (YMAB), and I-Mab (IMAB). These companies are all part of the "pharmaceutical products" industry.
Opus Genetics vs. Its Competitors
Neurogene (NASDAQ:NGNE) and Opus Genetics (NASDAQ:IRD) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk.
52.4% of Neurogene shares are held by institutional investors. Comparatively, 15.0% of Opus Genetics shares are held by institutional investors. 11.6% of Neurogene shares are held by insiders. Comparatively, 6.6% of Opus Genetics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
In the previous week, Neurogene had 5 more articles in the media than Opus Genetics. MarketBeat recorded 9 mentions for Neurogene and 4 mentions for Opus Genetics. Neurogene's average media sentiment score of 0.13 beat Opus Genetics' score of 0.05 indicating that Neurogene is being referred to more favorably in the media.
Neurogene has a net margin of 0.00% compared to Opus Genetics' net margin of -429.42%. Neurogene's return on equity of -36.16% beat Opus Genetics' return on equity.
Opus Genetics has higher revenue and earnings than Neurogene. Neurogene is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.
Neurogene has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500. Comparatively, Opus Genetics has a beta of -0.02, indicating that its share price is 102% less volatile than the S&P 500.
Neurogene currently has a consensus target price of $46.17, suggesting a potential upside of 130.32%. Opus Genetics has a consensus target price of $7.33, suggesting a potential upside of 633.33%. Given Opus Genetics' stronger consensus rating and higher probable upside, analysts clearly believe Opus Genetics is more favorable than Neurogene.
Summary
Neurogene beats Opus Genetics on 10 of the 16 factors compared between the two stocks.
Get Opus Genetics News Delivered to You Automatically
Sign up to receive the latest news and ratings for IRD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding IRD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Opus Genetics Competitors List
Related Companies and Tools
This page (NASDAQ:IRD) was last updated on 7/5/2025 by MarketBeat.com Staff
Free IRD Stock Alerts